Developing a new oral treatment to prevent gum infections caused by P. gingivalis
Official title: A Novel Peptide for the Oral Treatment and Prevention of P. Gingivalis Infection
Funded at Virtici, LLC · NIH-10819263 · Data updated 2026-11-12
This study is testing a new oral treatment that could help fight gum diseases by stopping harmful bacteria from sticking around in your mouth, and it’s looking for patients to help see how well it works and if it’s safe.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virtici, LLC NIH-funded |
| Lab location | 1 site (Seattle, UNITED STATES) |
| Project start | September 19, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $923,623 |
| NIH project number | 1R44DE033568-01 |
| Project ID | NIH-10819263 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults over the age of 30 who are at risk for or currently experiencing gum disease.
✕Less likely to help
Patients who do not have gum disease or are under 21 years old may not benefit from this research.
What this research studies
This research aims to create a novel oral peptide that can inhibit the bacteria P. gingivalis, which is responsible for gum diseases like gingivitis and periodontitis. By preventing this bacteria from adhering to other oral bacteria, the treatment could reduce inflammation and prevent tooth and bone loss. The approach involves understanding how P. gingivalis interacts with other bacteria in the mouth and developing a peptide that can disrupt this process. Patients may be involved in trials to test the effectiveness and safety of this new treatment.
Why it matters
Potential benefit: If successful, this research could lead to a new oral treatment that significantly reduces the incidence of gum disease and its associated health risks.
How similar studies have gone: Previous research has shown promise in targeting bacterial adherence to prevent infections, suggesting that this approach could be effective.
Where this research is happening
-
Virtici, LLC
Seattle, United States Active
Researchers
- Principal investigator: Fanger, Neil a — Virtici, LLC
- Study coordinator: Fanger, Neil a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.